ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 075

Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus

Taha Moussa1, Moussa Abdelhak 2 and Cuoghi Edens 3, 1University of Chicago Medicine, Chicago, 2Cambridge GPVTS, Cambridge, United Kingdom, 3University of Chicago, Chicago

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: CNS Lupus, juvenile SLE, neuropsychiatric disorders, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Poster Session 1

Session Type: ACR Abstract Session

Session Time: 6:00PM-7:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that typically affects multiple organs and can lead to potentially fatal complications. Management of SLE is always challenging and requires chronic use of immunotherapy in addition to systemic corticosteroids (CS). Central nervous system (CNS) involvement in SLE is common, especially in children, and can present nonspecifically with a variety of neuropsychiatric manifestations; described as neuropsychiatric lupus (NPSLE). Pseudotumor cerebri (PTC) is a term used to describe intracranial hypertension (ICH) which can be idiopathic or secondary to underlying etiology. Few cases of PTC in children with SLE have been reported without clear association. Here, we describe a case series of seven children who developed NPSLE in the form of PTC after diagnosis or as first manifestation of SLE to highlight the importance of proper neurologic evaluation of refractory headache in children with SLE.

Methods: Retrospective descriptive case series of 7 children (< 18 years old) who were diagnosed with SLE by a pediatric rheumatologist and PTC by pediatric neurologist at the time of or after their SLE diagnosis.

Results: All patients were adolescent females with either African American (AA) (5/7) or Hispanic (2/7) ethnicity. Refractory headaches were exhibited in 8/9 patients and obesity in 4/9 at the time of PCT diagnosis. Five of the patients had a prolonged history (≥ 9 months) of refractory headaches with multiple hospital admissions for investigation. SLE disease activity was severe in the majority of the patients based on the SLE Disease Activity Index (SLEDAI). Few patients had abnormal neuroimaging, history of NPSLE, abnormal CSF composition, abnormal neurologic examination or borderline CSF opening pressure. The diagnosis was supported specifically in those patients by failure of other measures to alleviate their refractory headache including controlling the underlying active lupus disease and remarkable improvement after therapeutic LP and acetazolamide treatment. Papilledema was absent in 3/7 patients on neurologic and ophthalmology examination (Table 1).

Conclusion: CNS involvement is common in children with SLE and PTC can be the first presentation. Intracranial hypertension is underestimated in children with SLE. Regardless of the term used to describe intracranial hypertension in SLE  (primary, secondary, NPSLE, ICH or PTC), it is still a treatable cause of significant morbidity among lupus patients. Vision loss is the most fearful complication of intracranial hypertension which can also develop in asymptomatic patients. Proper evaluation of intracranial hypertension through complete neurologic examination, ophthalmological examination, neuroimaging and CSF opening pressure should be considered in any lupus patient with refractory headache, 6th nerve palsy and/or papilledema. Regular fundus examination during SLE follow up visits is a convenient tool to detect asymptomatic PTC. In addition to appropriate control of underlying lupus disease, acetazolamide and therapeutic lumber puncture are successful measures to treat PTC in NPSLE.


Disclosure: T. Moussa, None; M. Abdelhak, None; C. Edens, None.

To cite this abstract in AMA style:

Moussa T, Abdelhak M, Edens C. Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/pseudotumor-cerebri-syndrome-in-children-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pseudotumor-cerebri-syndrome-in-children-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology